Based on the Thelansis market insight report on Adult-onset Still’s Disease (AoSD) which provides a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.
https://thelansis.com/reports/adult-onset-stills-disease-aosd-market-insight-report/
The annual incidence rate ranges 0.21 to 0.63 in 100,000 population and the prevalence rate varies between 1.05 to 1. 34 per 100,000 populations. The most common findings were fever (97.6%), arthralgia (95.2%), arthritis (76.2%), rash (73.8%) and sore throat (40.5%).
Comprehensive insight on patient segmentation based on age (18 to 90 yrs), sex, Incidence, Prevalence, Disease remission, Progression and severity (Mild, Moderate and severe), Biomarker segmentation (EOTAXIN (CCL11), FGF-2, G-CSF, GM-CSF, CXCL1, IL-17, IL-18, IL-6, IL-8, CXCL10, CCL2,3,4, TNF-?, VEGF), Signs & Symptoms, Clini-cal Manifestations (Fever, Arthritis, Skin Rash, Splenomegaly, Myalgia, Liver, Lymph nodes, Pericarditis, Pleuritis etc.), Treatment types (Anakinra, Canakinumab, tocilizumab, and other off labels) has been provided into the epidemiology section of the Adult-onset Still’s Disease (AoSD) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Cerecor Inc., AB2 Bio Ltd., Novartis Pharmaceuticals, Swedish Orphan Biovitrum, which are the companies building their assets to target Adult-onset Still’s disease (AoSD), However, companies like Hoffmann-La Roche, Pfizer, Chugai Pharmaceutical and Amgen are targeting Systemic Juvenile Idiopathic Arthritis. The payer’s and reimbursement agencies are more concerned about strong clinical outcomes data which have great evidence on managing the symptomatic conditions including quality of life, however, the cost could go up to USD 125,750 to USD 150,650 per year.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Scleroderma – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
Contact Information:
[email protected]
Tags:
PR-Wirein, Menafn, Reportedtimes, iCN Internal Distribution, Research Newswire, English
Add Comment